PMC:7170415 / 24670-25754 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"358","span":{"begin":969,"end":979},"obj":"Species"},{"id":"359","span":{"begin":788,"end":813},"obj":"Chemical"}],"attributes":[{"id":"A358","pred":"tao:has_database_id","subj":"358","obj":"Tax:2697049"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Nasopharyngeal swabs are the recommended specimen for molecular analysis. The sudden demand for flocked nasopharyngeal swabs and viral transport medium generated by the pandemic has put enormous pressures on supply chain capacities for these products. As of 19 March 2020 the CDC made oropharyngeal, mid-turbinate, and nasal swabs acceptable specimen types if nasopharyngeal swabs are not available (31). Early-morning posterior oropharyngeal saliva samples (coughed up by clearing the throat) also have been assessed as useful specimen types and would not require use of a swab (48). The CDC has released a standard operating procedure for laboratories to create their own viral transport medium (64); other solutions also may be used if viral transport medium is unavailable, including phosphate-buffered saline, liquid Amies, and normal saline (65). The FDA has provided guidance on its Web site for alternative materials to collect and transport samples for RT-PCR SARS–CoV-2 assays (34). The diagnostic value of molecular testing of nonrespiratory specimens currently is unclear."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T43","span":{"begin":304,"end":313},"obj":"Body_part"},{"id":"T44","span":{"begin":443,"end":449},"obj":"Body_part"},{"id":"T45","span":{"begin":486,"end":492},"obj":"Body_part"}],"attributes":[{"id":"A43","pred":"fma_id","subj":"T43","obj":"http://purl.org/sig/ont/fma/fma57456"},{"id":"A44","pred":"fma_id","subj":"T44","obj":"http://purl.org/sig/ont/fma/fma59862"},{"id":"A45","pred":"fma_id","subj":"T45","obj":"http://purl.org/sig/ont/fma/fma228738"}],"text":"Nasopharyngeal swabs are the recommended specimen for molecular analysis. The sudden demand for flocked nasopharyngeal swabs and viral transport medium generated by the pandemic has put enormous pressures on supply chain capacities for these products. As of 19 March 2020 the CDC made oropharyngeal, mid-turbinate, and nasal swabs acceptable specimen types if nasopharyngeal swabs are not available (31). Early-morning posterior oropharyngeal saliva samples (coughed up by clearing the throat) also have been assessed as useful specimen types and would not require use of a swab (48). The CDC has released a standard operating procedure for laboratories to create their own viral transport medium (64); other solutions also may be used if viral transport medium is unavailable, including phosphate-buffered saline, liquid Amies, and normal saline (65). The FDA has provided guidance on its Web site for alternative materials to collect and transport samples for RT-PCR SARS–CoV-2 assays (34). The diagnostic value of molecular testing of nonrespiratory specimens currently is unclear."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T23","span":{"begin":443,"end":449},"obj":"Body_part"},{"id":"T24","span":{"begin":486,"end":492},"obj":"Body_part"}],"attributes":[{"id":"A23","pred":"uberon_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/UBERON_0001836"},{"id":"A24","pred":"uberon_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/UBERON_0000341"}],"text":"Nasopharyngeal swabs are the recommended specimen for molecular analysis. The sudden demand for flocked nasopharyngeal swabs and viral transport medium generated by the pandemic has put enormous pressures on supply chain capacities for these products. As of 19 March 2020 the CDC made oropharyngeal, mid-turbinate, and nasal swabs acceptable specimen types if nasopharyngeal swabs are not available (31). Early-morning posterior oropharyngeal saliva samples (coughed up by clearing the throat) also have been assessed as useful specimen types and would not require use of a swab (48). The CDC has released a standard operating procedure for laboratories to create their own viral transport medium (64); other solutions also may be used if viral transport medium is unavailable, including phosphate-buffered saline, liquid Amies, and normal saline (65). The FDA has provided guidance on its Web site for alternative materials to collect and transport samples for RT-PCR SARS–CoV-2 assays (34). The diagnostic value of molecular testing of nonrespiratory specimens currently is unclear."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T104","span":{"begin":969,"end":973},"obj":"Disease"}],"attributes":[{"id":"A104","pred":"mondo_id","subj":"T104","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Nasopharyngeal swabs are the recommended specimen for molecular analysis. The sudden demand for flocked nasopharyngeal swabs and viral transport medium generated by the pandemic has put enormous pressures on supply chain capacities for these products. As of 19 March 2020 the CDC made oropharyngeal, mid-turbinate, and nasal swabs acceptable specimen types if nasopharyngeal swabs are not available (31). Early-morning posterior oropharyngeal saliva samples (coughed up by clearing the throat) also have been assessed as useful specimen types and would not require use of a swab (48). The CDC has released a standard operating procedure for laboratories to create their own viral transport medium (64); other solutions also may be used if viral transport medium is unavailable, including phosphate-buffered saline, liquid Amies, and normal saline (65). The FDA has provided guidance on its Web site for alternative materials to collect and transport samples for RT-PCR SARS–CoV-2 assays (34). The diagnostic value of molecular testing of nonrespiratory specimens currently is unclear."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T225","span":{"begin":178,"end":181},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T226","span":{"begin":276,"end":279},"obj":"http://purl.obolibrary.org/obo/CL_0000990"},{"id":"T227","span":{"begin":419,"end":428},"obj":"http://purl.obolibrary.org/obo/UBERON_0001353"},{"id":"T228","span":{"begin":572,"end":573},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T229","span":{"begin":580,"end":582},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"},{"id":"T230","span":{"begin":589,"end":592},"obj":"http://purl.obolibrary.org/obo/CL_0000990"},{"id":"T231","span":{"begin":593,"end":596},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T232","span":{"begin":606,"end":607},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T233","span":{"begin":861,"end":864},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T234","span":{"begin":988,"end":990},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"},{"id":"T235","span":{"begin":1027,"end":1034},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"}],"text":"Nasopharyngeal swabs are the recommended specimen for molecular analysis. The sudden demand for flocked nasopharyngeal swabs and viral transport medium generated by the pandemic has put enormous pressures on supply chain capacities for these products. As of 19 March 2020 the CDC made oropharyngeal, mid-turbinate, and nasal swabs acceptable specimen types if nasopharyngeal swabs are not available (31). Early-morning posterior oropharyngeal saliva samples (coughed up by clearing the throat) also have been assessed as useful specimen types and would not require use of a swab (48). The CDC has released a standard operating procedure for laboratories to create their own viral transport medium (64); other solutions also may be used if viral transport medium is unavailable, including phosphate-buffered saline, liquid Amies, and normal saline (65). The FDA has provided guidance on its Web site for alternative materials to collect and transport samples for RT-PCR SARS–CoV-2 assays (34). The diagnostic value of molecular testing of nonrespiratory specimens currently is unclear."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T38","span":{"begin":788,"end":797},"obj":"Chemical"}],"attributes":[{"id":"A38","pred":"chebi_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/CHEBI_18367"},{"id":"A39","pred":"chebi_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/CHEBI_26020"},{"id":"A40","pred":"chebi_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/CHEBI_35780"},{"id":"A41","pred":"chebi_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/CHEBI_43474"}],"text":"Nasopharyngeal swabs are the recommended specimen for molecular analysis. The sudden demand for flocked nasopharyngeal swabs and viral transport medium generated by the pandemic has put enormous pressures on supply chain capacities for these products. As of 19 March 2020 the CDC made oropharyngeal, mid-turbinate, and nasal swabs acceptable specimen types if nasopharyngeal swabs are not available (31). Early-morning posterior oropharyngeal saliva samples (coughed up by clearing the throat) also have been assessed as useful specimen types and would not require use of a swab (48). The CDC has released a standard operating procedure for laboratories to create their own viral transport medium (64); other solutions also may be used if viral transport medium is unavailable, including phosphate-buffered saline, liquid Amies, and normal saline (65). The FDA has provided guidance on its Web site for alternative materials to collect and transport samples for RT-PCR SARS–CoV-2 assays (34). The diagnostic value of molecular testing of nonrespiratory specimens currently is unclear."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T21","span":{"begin":129,"end":144},"obj":"http://purl.obolibrary.org/obo/GO_0046794"},{"id":"T22","span":{"begin":135,"end":144},"obj":"http://purl.obolibrary.org/obo/GO_0006810"},{"id":"T23","span":{"begin":674,"end":689},"obj":"http://purl.obolibrary.org/obo/GO_0046794"},{"id":"T24","span":{"begin":680,"end":689},"obj":"http://purl.obolibrary.org/obo/GO_0006810"},{"id":"T25","span":{"begin":739,"end":754},"obj":"http://purl.obolibrary.org/obo/GO_0046794"},{"id":"T26","span":{"begin":745,"end":754},"obj":"http://purl.obolibrary.org/obo/GO_0006810"},{"id":"T27","span":{"begin":940,"end":949},"obj":"http://purl.obolibrary.org/obo/GO_0006810"}],"text":"Nasopharyngeal swabs are the recommended specimen for molecular analysis. The sudden demand for flocked nasopharyngeal swabs and viral transport medium generated by the pandemic has put enormous pressures on supply chain capacities for these products. As of 19 March 2020 the CDC made oropharyngeal, mid-turbinate, and nasal swabs acceptable specimen types if nasopharyngeal swabs are not available (31). Early-morning posterior oropharyngeal saliva samples (coughed up by clearing the throat) also have been assessed as useful specimen types and would not require use of a swab (48). The CDC has released a standard operating procedure for laboratories to create their own viral transport medium (64); other solutions also may be used if viral transport medium is unavailable, including phosphate-buffered saline, liquid Amies, and normal saline (65). The FDA has provided guidance on its Web site for alternative materials to collect and transport samples for RT-PCR SARS–CoV-2 assays (34). The diagnostic value of molecular testing of nonrespiratory specimens currently is unclear."}

{"project":"LitCovid-sentences","denotations":[{"id":"T172","span":{"begin":0,"end":73},"obj":"Sentence"},{"id":"T173","span":{"begin":74,"end":251},"obj":"Sentence"},{"id":"T174","span":{"begin":252,"end":404},"obj":"Sentence"},{"id":"T175","span":{"begin":405,"end":584},"obj":"Sentence"},{"id":"T176","span":{"begin":585,"end":852},"obj":"Sentence"},{"id":"T177","span":{"begin":853,"end":992},"obj":"Sentence"},{"id":"T178","span":{"begin":993,"end":1084},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Nasopharyngeal swabs are the recommended specimen for molecular analysis. The sudden demand for flocked nasopharyngeal swabs and viral transport medium generated by the pandemic has put enormous pressures on supply chain capacities for these products. As of 19 March 2020 the CDC made oropharyngeal, mid-turbinate, and nasal swabs acceptable specimen types if nasopharyngeal swabs are not available (31). Early-morning posterior oropharyngeal saliva samples (coughed up by clearing the throat) also have been assessed as useful specimen types and would not require use of a swab (48). The CDC has released a standard operating procedure for laboratories to create their own viral transport medium (64); other solutions also may be used if viral transport medium is unavailable, including phosphate-buffered saline, liquid Amies, and normal saline (65). The FDA has provided guidance on its Web site for alternative materials to collect and transport samples for RT-PCR SARS–CoV-2 assays (34). The diagnostic value of molecular testing of nonrespiratory specimens currently is unclear."}